Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Is Wall Street Bullish or Bearish on Hologic Stock?

February 10, 2026 at 08:57 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

With a market cap of $16.7 billion, Hologic, Inc. (HOLX) is a global medical technology company focused on improving women’s health through the early detection and treatment of disease. It develops and supplies diagnostic assays, medical imaging systems, and surgical solutions across its Diagnostics, Breast Health, GYN Surgical, and Skeletal Health segments.

Shares of the Marlborough, Massachusetts-based company have slightly outperformed the broader market over the past 52 weeks. HOLX stock has increased 16.2% over this time frame, while the broader S&P 500 Index ($SPX) has gained 15.6%. However, the stock has risen marginally on a YTD basis, slightly lagging behind SPX's 1.7% return.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

Looking closer, shares of the medical device maker have outpaced the State Street Health Care Select Sector SPDR ETF's (XLV) 6.8% return over the past 52 weeks.

Shares of Hologic fell marginally following its Q1 2026 results on Jan. 29. Adjusted EPS came in at $1.04 and revenue totaled $1.05 billion, both below expectations. Investor sentiment was further pressured by weakness in Diagnostics revenue, margin compression from $15.3 million in tariff-related costs, and the company’s decision not to provide forward guidance due to its pending acquisition by Blackstone and TPG.

For the fiscal year ending in September 2026, analysts expect HOLX’s adjusted EPS to grow 4.9% year-over-year to $4.47. The company's earnings surprise history is mixed. It topped the consensus estimates in three of the last four quarters while missing on another occasion.

Among the 18 analysts covering the stock, the consensus rating is a “Hold.”

The mean price target of $75.58 represents a marginal premium to HOLX's current price. The Street-high price target of $79 suggests a 5.3% potential upside.

On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article